GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kilitch Drugs (India) Ltd (BOM:524500) » Definitions » Interest Expense

Kilitch Drugs (India) (BOM:524500) Interest Expense : ₹-50 Mil (TTM As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Kilitch Drugs (India) Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kilitch Drugs (India)'s interest expense for the three months ended in Sep. 2024 was ₹ -3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-50 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kilitch Drugs (India)'s Operating Income for the three months ended in Sep. 2024 was ₹ 55 Mil. Kilitch Drugs (India)'s Interest Expense for the three months ended in Sep. 2024 was ₹ -3 Mil. Kilitch Drugs (India)'s Interest Coverage for the quarter that ended in Sep. 2024 was 17.96. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kilitch Drugs (India) Interest Expense Historical Data

The historical data trend for Kilitch Drugs (India)'s Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kilitch Drugs (India) Interest Expense Chart

Kilitch Drugs (India) Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.16 -7.54 -11.98 -49.19 -59.29

Kilitch Drugs (India) Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.09 -15.99 -13.22 -17.32 -3.06

Kilitch Drugs (India) Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kilitch Drugs (India)  (BOM:524500) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kilitch Drugs (India)'s Interest Expense for the three months ended in Sep. 2024 was ₹-3 Mil. Its Operating Income for the three months ended in Sep. 2024 was ₹55 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was ₹0 Mil.

Kilitch Drugs (India)'s Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Interest Coverage=-1* Operating Income (Q: Sep. 2024 )/Interest Expense (Q: Sep. 2024 )
=-1*54.877/-3.055
=17.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Kilitch Drugs (India) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kilitch Drugs (India) Ltd (BOM:524500) » Definitions » Interest Expense
Comparable Companies
BOM:532039 BOM:539730 BOM:526953 BOM:530477 BOM:541096 BOM:524075 BOM:539997 BOM:524654 BOM:532408 BOM:532305 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
KILITCH:India
Address
Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Website
https://www.kilitch.com
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in the manufacture and sales of pharmaceutical products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, HPURE, and others. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.

Kilitch Drugs (India) Headlines

No Headlines